Theriva Biologics Files 8-K: Regulation FD, Other Events
Ticker: TOVX · Form: 8-K · Filed: Jul 31, 2024 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 8-K |
| Filed Date | Jul 31, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.22 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulatory
TL;DR
Theriva Biologics dropped an 8-K on 7/30 covering Reg FD and other events. Check it out.
AI Summary
On July 30, 2024, Theriva Biologics, Inc. (formerly Synthetic Biologics, Inc.) filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial statements and exhibits. The company is incorporated in Nevada and its fiscal year ends on December 31.
Why It Matters
This 8-K filing provides important updates and disclosures from Theriva Biologics, Inc., which could impact investor understanding of the company's current status and regulatory compliance.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for disclosures and does not indicate any immediate financial distress or significant negative events.
Key Players & Entities
- Theriva Biologics, Inc. (company) — Registrant
- Synthetic Biologics, Inc. (company) — Former Company Name
- July 30, 2024 (date) — Earliest event reported date
- Nevada (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing by Theriva Biologics, Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure, Other Events, and to include Financial Statements and Exhibits, as of July 30, 2024.
What was Theriva Biologics, Inc. previously known as?
Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc.
In which U.S. state is Theriva Biologics, Inc. incorporated?
Theriva Biologics, Inc. is incorporated in Nevada.
What is the fiscal year end for Theriva Biologics, Inc.?
The fiscal year end for Theriva Biologics, Inc. is December 31.
What is the Commission File Number for Theriva Biologics, Inc.?
The Commission File Number for Theriva Biologics, Inc. is 001-12584.
Filing Stats: 765 words · 3 min read · ~3 pages · Grade level 10.2 · Accepted 2024-07-31 08:20:14
Key Financial Figures
- $0.001 — h registered Common stock, par value $0.001 per share TOVX NYSE American Indica
- $1.22 — s common stock at a conversion price of $1.22 per share. Item 9.01. Financial State
Filing Documents
- tm2420486d1_8k.htm (8-K) — 29KB
- tm2420486d1_ex99-1.htm (EX-99.1) — 13KB
- tm2420486d1_ex99-1img001.jpg (GRAPHIC) — 7KB
- 0001104659-24-084159.txt ( ) — 228KB
- syn-20240730.xsd (EX-101.SCH) — 3KB
- syn-20240730_lab.xml (EX-101.LAB) — 33KB
- syn-20240730_pre.xml (EX-101.PRE) — 22KB
- tm2420486d1_8k_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On July 30, 2024, Theriva Biologics, Inc. (the "Company") received notice from the U.S. Food and Drug Administration (FDA) that it had been granted Rare Pediatric Drug Designation (RPDD) for VCN-01 for the treatment of retinoblastoma. VCN-01, the Company's lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. Previously, the FDA granted orphan drug designation to VCN-01 for treatment of retinoblastoma. On July 31, 2024, the Company issued a press release announcing that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Drug Designation (RPDD) for VCN-01 for the treatment of retinoblastoma. The information in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.
01. Other Events
Item 8.01. Other Events. Rare Pediatric Drug Designation On July 30, 2024, the Company received notice from the U.S. Food and Drug Administration (FDA) that it had been granted Rare Pediatric Drug Designation (RPDD) for VCN-01 for the treatment of retinoblastoma. VCN-01, the Company's lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. Previously, the FDA granted orphan drug designation to VCN-01 for treatment of retinoblastoma. Series C Convertible Preferred Stock Conversion On July 30, 2024, the Company received a notice of conversion from the holder of shares of its Series C Convertible Preferred Stock to convert the 135,431 shares of Series C Convertible Preferred Stock into 888,072 shares of the Company's common stock at a conversion price of $1.22 per share.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by Theriva Biologics, Inc., dated July 31, 2024 104 Cover Page Interactive Data File (embedded within the XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: July 31, 2024 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer